PURPOSE: To evaluate the short and long-term effects of @entity706 ( @entity706 ) in the treatment of @entity299 . METHODS AND MATERIALS: Between 1986 and 1995, 48 courses of @entity706 were delivered to 47 cardiac transplant @entity1 . In 37 @entity1 , @entity706 was administered for intractable allograft rejection despite conventional therapy while 10 @entity1 received @entity706 prophylactically. The prescribed radiation dose was 8 Gy in 0.8 Gy fractions twice weekly to mantle and inverted-Y plus spleen fields. Postirradiation follow-up ranged from 6 months to 9.1 years, with a mean of 3.1 years. RESULTS: The actual mean dose was 7.3 Gy delivered over a mean of 39 days. Fifty-six percent of @entity1 required treatment delay or abbreviation because of @entity882 , @entity1431 , @entity281 , or unrelated problems. In @entity1 treated for intractable rejection, rejection rates dropped from 0.46 to 0.14 and to 0.06 episodes/ @entity1 /month before, during, and after @entity706 (p < 0.0001). Rejection rates continued to drop throughout follow-up. @entity229 requirements decreased from 0.41 mg/kg before treatment to 0.21 mg/kg afterward (p < 0.0001). The ratio of helper to cytotoxic-suppressor T-cells decreased during @entity706 from 1.33 to 0.89, and remained low at 0.44, 2-4 months after treatment. Infection rates were not increased and two @entity1 developed @entity5 . Rejection rates were high during prophylactic treatment and this protocol was abandoned. Three-year actuarial survival after irradiation was 60% for @entity1 with intractable rejection and 70% for the prophylactic cohort. CONCLUSION: @entity706 is an effective treatment for control of intractable cardiac rejection. Episodes of rejection and @entity134 dosage requirements are decreased for up to 9.1 years. A possible mechanism of action is long term alteration in T-lymphocyte subsets. @entity1 experience transient @entity236 but no increase in @entity281 or @entity548 . Long-term complications of @entity706 are not appreciably different than conventional immunosuppression.

Long-term results of XXXX in the treatment of cardiac allograft rejection.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity706 :: ('MESH:D008223', 'Disease') :: ['TLI', 'total lymphoid irradiation'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['Prednisone'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac transplant rejection'] @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow suppression']
@entity706 :: (MESH:D008223,Disease) :: ['total lymphoid irradiation']
